Geode Capital Management LLC Sells 530 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Geode Capital Management LLC reduced its stake in Inari Medical, Inc. (NASDAQ:NARI) by 0.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 1,213,205 shares of the company’s stock after selling 530 shares during the quarter. Geode Capital Management LLC’s holdings in Inari Medical were worth $61,949,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Jane Street Group LLC increased its holdings in shares of Inari Medical by 32.4% in the third quarter. Jane Street Group LLC now owns 95,223 shares of the company’s stock worth $3,927,000 after purchasing an additional 23,286 shares during the last quarter. Barclays PLC increased its stake in Inari Medical by 9.7% in the 3rd quarter. Barclays PLC now owns 288,079 shares of the company’s stock worth $11,881,000 after acquiring an additional 25,365 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Inari Medical by 2.2% during the 3rd quarter. Franklin Resources Inc. now owns 223,810 shares of the company’s stock worth $9,445,000 after acquiring an additional 4,899 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Inari Medical by 66.8% during the 4th quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock valued at $100,000 after acquiring an additional 786 shares during the last quarter. Finally, AMI Asset Management Corp purchased a new position in shares of Inari Medical in the fourth quarter valued at $1,651,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Inari Medical Price Performance

NARI stock opened at $79.97 on Friday. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $79.99. The firm’s 50-day moving average is $79.95 and its 200 day moving average is $64.30. The company has a market capitalization of $4.68 billion, a PE ratio of -59.24 and a beta of 1.02.

Wall Street Analyst Weigh In

Several research firms have commented on NARI. Oppenheimer initiated coverage on shares of Inari Medical in a research report on Tuesday, December 17th. They set an “outperform” rating and a $75.00 price objective for the company. BTIG Research reiterated a “neutral” rating on shares of Inari Medical in a research report on Wednesday, January 8th. William Blair restated a “market perform” rating on shares of Inari Medical in a research report on Tuesday, January 7th. Robert W. Baird reiterated a “neutral” rating and issued a $80.00 target price (down previously from $81.00) on shares of Inari Medical in a report on Tuesday, January 7th. Finally, Canaccord Genuity Group restated a “hold” rating and set a $80.00 price target (up previously from $74.00) on shares of Inari Medical in a report on Tuesday, January 7th. Twelve equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $68.00.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.